Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, has expanded an existing license agreement for the development of new therapeutics using their own PROTAC technology.  The multi-year strategic collaboration initiated in October 2015 with Genentech will now encompass additional disease targets.   The PROTAC platform removes target proteins directly rather than inhibiting them. This differs from small molecule inhibitors, which often ...